Table 1. Baseline demographics and clinical characteristics across different treatment groups.
| Clinical characteristics N (%) | Discovery Cohort | Validation Cohort |
||
|---|---|---|---|---|
| Bevacizumab group | Control group | P-valuea | ||
| No. of patients | 64 | 91 | 95 | — |
| Age at diagnosis | 52 (26–77) | 53 (21–76) | 55 (26–83) | 0.93 |
| Sex | 0.45 | |||
| male | 35 (56.5) | 59 (60.2) | 56 (63.6) | |
| female | 27 (43.5) | 39 (39.8) | 32 (36.4) | |
| Location of primary tumor | 0.54 | |||
| colon | 42 (67.7) | 62 (68.1) | 60 (63.2) | |
| rectum | 20 (32.3) | 29 (31.9) | 35 (36.8) | |
| ECOG performance status | 0.94 | |||
| 0–1 | 84 (95.5.) | 92 (97.9) | 84 (95.5) | |
| ≥2 | 4 (4.5) | 2 (2.1) | 4 (3.5) | |
| Pathology | 0.73 | |||
| moderately differentiated | 40 (65.6) | 55 (69.6) | 60 (73.2) | |
| poorly differentiated | 21 (34.4) | 24 (30.4) | 22 (26.8) | |
| Matestasis | 0.30 | |||
| single | 31 (50.0) | 46 (50.5) | 56 (58.9) | |
| multiple | 31 (50.0) | 45 (49.5) | 39 (41.1) | |
| Curative-intent matestasis resection | 6 (9.7) | 17 (18.7) | 19 (20.0) | 0.86 |
| Backbone chemotherapy | 0.28 | |||
| oxaliplatin-based | 36 (56.2) | 63 (70.0) | 57 (61.3) | |
| irinotecan-based | 28 (43.8) | 27 (30.0) | 36 (38.7) | |
| Prior adjuvant chemotherapy | 17 (27.4) | 30 (31.6) | 23 (25.8) | 0.42 |
| Recurrent diseaseb | 17 (27.4) | 23 (25.3) | 31 (32.6) | 0.33 |
| First-line duration of CT (median, mos) | 5 (3.0–18.0) | 4.5 (1.5- 25.0) | 3.8 (2.5–24.0) | 0.18 |
| Total duration of CT (median, mos) | 12 (3.0–22.0) | 9.5 (2.0–25.0) | 11.5 (2.5–26.0) | 0.60 |
| Second-line treatment | 23 (39.0) | 17 (23.3) | 14 (15.9) | 0.27 |
| Anti-EGFR treatment following first PD | 3 (4.8) | 22 (24.7) | 31 (32.6) | 0.26 |
| Maintenance treatmentc | 20 (32.3) | 10 (13.3) | 14 (15.6) | 0.83 |
aCompared patient characteristics between the bevacizumab group and the control group.
bPatients who had metastatic disease more than 6 months elapsed from adjuvant chemotherapy.
cMonotherapy of capecitabine or bevacizumab, or combined with both. Abbreviations: ECOG PS, eastern cooperative oncology group performance status; EGFR, epidermal growth factor receptor; CT, chemotherapy; mos, months. Statistical significance was set at 0.05 based on a two-sided test. P-values listed in bold were notable for possible association with clinical outcomes.